Skip to content
Sun Pharma logo

Sun Pharma

Sun Pharmaceutical Industries Ltd

SUNPHARMA NSE
₹1,773.40 +3.50 (+0.20%)
P/E
38.81
View as Markdown
MCP
Close 4 Nov 2026 ₹1,773.40 +87.50 +5.19% 1Y
Start ₹1,685.90

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
20.50%
Debt to Equity
0.04
EPS (TTM)
₹45.70
Book Value
₹372.10
Market Cap
—
P/E (TTM)
38.81
P/B
4.77
ROE
16.00%
Dividend Yield
0.90%
EBITDA
₹19,703 Cr
52W High
₹2,046.90
52W Low
₹1,583.70
Day Range
₹1,769.00 – ₹1,810.40
Volume
49,25,315

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Sun Pharma peer comparison
Sun Pharma (this company)
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Median 7 companies₹1,773.4038.81₹1,25,446 Cr4.770.58%16.50%17.80%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 100/100

Category scores

Quality
55
Average
Returns, margins, earnings quality 22% weight
Valuation
71
Strong
Cheap vs sector & own history 24% weight
Growth
30
Poor
Sales & profit trajectory 9% weight
Financial Health
80
Strong
Solvency, leverage, coverage 9% weight
Momentum
14
Poor
Trend strength, vol-adjusted 12% weight
Ownership
31
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 34.1%

Weaknesses

2
  • Promoter holding has decreased over last quarter: -1.80%
  • The company has delivered a poor sales growth of 11.8% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral757
OscillatorsBullish153
Moving AveragesStrong Bearish604

Key readings

RSI (14)
46.83
Neutral
MACD (12,26,9)
−15.47
Bullish
SMA (50)
1,826.95
Bearish
SMA (200)
1,808.84
Bearish

As of

Analyst Rating

Based on 32 analysts
BUY88%

28 of 32 analysts rate Buy, 1 Hold, 3 Sell.

As of

BUY
28
88%
HOLD
1
3%
SELL
3
9%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+7.45%
5Y+11.78%
3Y+10.03%
1Y+11.19%
TTM+12.13%

Net profit

Net profit growth by window
10Y+7.36%
5Y+38.33%
3Y+10.57%
1Y+4.96%
TTM+4.79%

Operating cash flow

Operating cash flow growth by window
10Y+6.39%
5Y+15.02%
3Y+35.80%
1Y−11.75%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.46 pp
5Y+2.94 pp
3Y+1.68 pp
1Y−0.52 pp
TTM−0.81 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹31,578 Cr
Mar 2018₹26,489 Cr
Mar 2019₹29,066 Cr
Mar 2020₹32,838 Cr
Mar 2021₹33,498 Cr
Mar 2022₹38,654 Cr
Mar 2023₹43,886 Cr
Mar 2024₹48,497 Cr
Mar 2025₹52,578 Cr
Mar 2026₹58,462 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹7,846 Cr
Mar 2018₹2,542 Cr
Mar 2019₹3,208 Cr
Mar 2020₹4,172 Cr
Mar 2021₹2,272 Cr
Mar 2022₹3,389 Cr
Mar 2023₹8,513 Cr
Mar 2024₹9,610 Cr
Mar 2025₹10,965 Cr
Mar 2026₹11,509 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹5,012 Cr +28.7% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk medium

Sun Pharmaceutical Industries trades at ₹1,777.7 as of 2026-10-30 with a market cap of ₹4,30,489 crore and a PE of 38.9x. The company is virtually debt-free with a debt-to-equity ratio of 0.06, has compounded profits at 17% over five years, and maintains an ROE of 13.79%, though recent TTM profit growth has moderated to 7%.

Bull Case 8
  • Near debt-free balance sheet with a debt-to-equity ratio of just 0.06, providing significant financial flexibility and resilience through economic cycles.
  • Strong five-year compounded profit growth of 17%, outpacing the ten-year CAGR of 10%, indicating an improving earnings trajectory over the medium term.
  • Five-year compounded sales growth of 12% and TTM sales growth of 12% suggest the revenue momentum has been sustained at a healthy clip.
  • ROCE of 17.94% reflects efficient capital deployment, comfortably above typical cost-of-capital benchmarks for large-cap pharma companies.
  • Consistent return on equity averaging 16% over the last three and five years, with the last full year also at 16%, points to stable profitability.
  • Healthy dividend payout ratio of 34.1% signals disciplined capital allocation and a willingness to share profits with shareholders, with a current yield of 0.91%.
  • Stock price CAGR of 17% over both three-year and five-year periods demonstrates sustained long-term wealth creation for shareholders.
  • Trading roughly 13% below its 52-week high of ₹2,046.9 as of 2026-10-30, the stock has pulled back from peak levels, potentially offering a more palatable entry zone relative to recent highs.
Bear Case 7
  • TTM PE of 38.9x is elevated for a large-cap pharma name, implying the market is pricing in significant future growth that may already be baked in.
  • TTM profit growth has decelerated sharply to 7% compared to the five-year CAGR of 17%, suggesting earnings momentum may be fading.
  • Promoter holding declined by 1.80% in the most recent quarter, which can signal reduced insider confidence or potential share supply overhang.
  • Ten-year compounded sales growth of only 7% highlights that the top-line expansion over a longer horizon has been relatively modest for a company of this valuation.
  • ROE of 13.79% as of the latest period is below the three-year and five-year averages of 16%, pointing to a near-term dip in return efficiency.
  • Dividend yield of 0.91% is modest relative to the high PE multiple, meaning investors are relying predominantly on capital appreciation rather than income.
  • One-year stock CAGR of just 5% versus the five-year CAGR of 17% indicates that recent share price performance has considerably lagged its own longer-term trend.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Sun Pharma is showing steady momentum in specialty therapeutics, with its oncology drug UNLOXCYT gaining a preferred guideline designation and continued investment in dermatology via a $2.5M academic endowment. No material headwinds emerged in this period. Corporate actions like ESOP approvals and a proposed ₹15,000 crore NCD issue suggest the company is positioning for sustained growth and financial flexibility. The near-term trend remains constructive, with specialty pipeline progress being the key catalyst to watch.

Positives 2
  • UNLOXCYT gets NCCN preferred nod Oct 20

    UNLOXCYT received Category 2A Preferred Designation in guidelines for locally advanced cutaneous squamous cell carcinoma, strengthening Sun Pharma's oncology portfolio.

  • $2.5M Mount Sinai professorship Oct 6

    Sun Pharma established a $2.5 million endowed professorship in dermatology at Mount Sinai, reinforcing its commitment to dermatology research and brand positioning.

Neutral 2
  • ESOP 2026 and borrowing limits approved Oct 31

    Seven special resolutions passed via postal ballot on October 31, including a new ESOP 2026 plan and enhanced borrowing limits under Section 180(1)(c) of the Companies Act.

  • NCD issue up to ₹15,000 crore Oct 7

    Board met on October 12 to consider issuing unsecured, rated NCDs up to ₹15,000 crore via private placement, signalling potential capital raising for growth or refinancing.

Quarterly Results

₹ Cr
SUNPHARMA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
12,192
12,381
11,983
12,653
13,291
13,675
12,959
13,851
14,478
15,521
14,612
15,300
16,199
Expenses
9,013
8,904
8,948
9,045
9,352
9,666
9,243
9,550
9,951
10,572
10,658
10,882
11,455
Operating Profit
3,179
3,477
3,035
3,608
3,939
4,009
3,716
4,302
4,527
4,948
3,954
4,418
4,744
OPM %
26%
28%
25%
29%
30%
29%
29%
31%
31%
32%
27%
29%
29%
Other Income
294
180
504
533
354
149
251
−354
470
89
458
520
−752
Interest
49
35
74
62
69
52
49
75
100
78
86
100
75
Depreciation
633
622
650
655
626
631
664
701
730
732
775
739
758
PBT
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
4,227
3,551
4,099
3,159
Tax %
14%
14%
5%
16%
16%
16%
34%
27%
25%
20%
23%
29%
37%
Net Profit
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
3,381
2,710
2,901
1,995
EPS (₹)
9.9
10.52
11.06
11.82
12.67
12.1
8.96
9.5
13
14.04
11.31
12.06
8.29

Profit & Loss

₹ Cr
SUNPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
27,392
28,487
31,578
26,489
29,066
32,838
33,498
38,654
43,886
48,497
52,578
58,462
61,631
Expenses
19,498
20,313
21,476
20,858
22,689
25,855
25,028
28,397
32,235
35,479
37,464
41,961
43,567
Operating Profit
7,894
8,174
10,102
5,631
6,377
6,983
8,470
10,258
11,650
13,018
15,114
16,501
18,064
OPM %
29%
29%
32%
21%
22%
21%
25%
27%
27%
27%
29%
28%
29%
Other Income
283
−42
610
−135
−258
382
−3,449
−3,505
459
865
1,444
1,895
316
Interest
579
523
400
518
555
303
141
127
172
238
231
339
339
Depreciation
1,195
1,038
1,265
1,500
1,753
2,053
2,080
2,144
2,529
2,557
2,575
2,938
3,005
PBT
6,403
6,571
9,048
3,479
3,810
5,010
2,799
4,481
9,408
11,088
13,752
15,119
15,037
Tax %
14%
14%
13%
26%
16%
16%
18%
24%
9%
13%
20%
24%
—
Net Profit
5,476
5,658
7,846
2,542
3,208
4,172
2,272
3,389
8,513
9,610
10,965
11,509
10,987
EPS (₹)
21.92
18.89
29.03
8.73
11.11
15.69
12.1
13.64
35.32
39.91
45.55
47.84
45.7
Div. Payout %
14%
5%
12%
23%
25%
25%
62%
73%
33%
34%
35%
33%
—

Balance Sheet

₹ Cr
SUNPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
207
241
240
240
240
240
240
240
240
240
240
240
240
Reserves
25,431
32,742
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
83,330
89,040
Borrowings
8,996
8,497
9,832
10,385
10,514
8,315
3,869
1,290
6,886
3,274
2,362
4,627
3,241
Other Liabilities
14,089
13,948
14,624
15,598
12,666
14,615
17,291
20,474
17,831
18,387
17,328
20,210
22,317
Total Liabilities
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
1,14,838
Fixed Assets
12,682
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
32,822
35,110
CWIP
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
3,052
1,864
Investments
2,716
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
24,723
16,449
Other Assets
31,286
35,550
39,427
35,837
33,439
33,984
34,890
32,975
36,849
41,700
44,324
47,811
61,415
Total Assets
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
1,14,838

Cash Flow

₹ Cr
SUNPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
12,419
Investing
−1,502
−3,949
−4,186
−3,104
−310
−2,225
407
−5,556
−7,220
−763
−5,183
−10,405
Financing
−1,187
−1,889
−2,285
−1,539
−2,731
−5,715
−5,980
−5,193
2,376
−6,710
−7,906
−2,513
Net Cash Flow
2,927
848
611
−736
−844
−1,386
596
−1,765
115
4,662
983
−498
Free Cash Flow
3,316
3,353
3,492
2,013
−966
5,105
5,097
7,550
2,895
9,964
12,005
8,906
CFO/EBITDA
93
106
90
83
48
113
85
78
56
105
96
89

Ratios

SUNPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
87
83
108
112
105
99
99
95
85
91
97
Inventory Days
307
370
307
338
366
311
378
315
360
338
348
363
Days Payable
178
207
197
234
192
142
167
158
194
194
210
232
Cash Conversion Cycle
197
251
193
212
285
274
310
255
261
229
228
228
Working Capital Days
−7
37
−4
−31
31
51
51
47
40
55
65
54
ROCE %
23%
18%
20%
10%
10%
10%
13%
17%
16%
17%
20%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sun Pharma insights

70 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.68%
  • DIIs 22.27%
  • FIIs 14.36%
  • Public 6.71%
  • Others 3.99%

0.01% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Sun Pharma

What does Sun Pharmaceutical Industries Ltd do?
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs).
Where is Sun Pharmaceutical Industries Ltd (SUNPHARMA) listed?
Sun Pharmaceutical Industries Ltd trades as SUNPHARMA on the NSE and under code 524715 on the BSE.
Which sector does Sun Pharmaceutical Industries Ltd belong to?
Sun Pharmaceutical Industries Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the PE ratio of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd trades at a PE ratio of 38.81 as of 4 Nov 2026, on earnings per share of ₹45.7, against a book value of ₹372.1 per share.
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?
Over the last 52 weeks Sun Pharmaceutical Industries Ltd has traded between ₹1,583.7 and ₹2,046.9 as of 4 Nov 2026.
Does Sun Pharmaceutical Industries Ltd pay dividends?
Sun Pharmaceutical Industries Ltd has a dividend yield of 0.90%.
What is the Return on Equity (ROE) of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd reported a return on equity of 16.00%. Its debt-to-equity ratio is 0.04.

Company Information

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.

Website sunpharma.com
CEO Mr. Dilip Shantilal Shanghvi
Employees 43,000
Listed 8 Feb 1995
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUNPHARMA.md for Sun Pharmaceutical Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month